2-(difluoromethyl)benzenesulfonamide | 161525-57-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(difluoromethyl)benzenesulfonamide
• 英文别名: 2-(Difluoromethyl)benzenesulfonamide
• CAS: 161525-57-1
• 化学式: C₇H₇F₂NO₂S
• 分子量: 207.201
• InChiKey: VECCQNWGOLBAJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  光气 、 2-(difluoromethyl)benzenesulfonamide 在 氯化亚砜 作用下， 反应 7.0h， 以95%的产率得到2-Difluoromethyl-benzenesulfonyl isocyanate
  参考文献：
  名称：

  New fluoro intermediates for herbicidal sulfonylureas

  摘要：

  DOI：

  10.1002/(sici)1096-9063(199905)55:5<566::aid-ps949>3.0.co;2-f
• 作为产物：
  描述：

  (difluoromethyl)benzene-1-sulfonyl chloride 在 ammonium hydroxide 作用下， 以71%的产率得到2-(difluoromethyl)benzenesulfonamide
  参考文献：
  名称：

  New fluoro intermediates for herbicidal sulfonylureas

  摘要：

  DOI：

  10.1002/(sici)1096-9063(199905)55:5<566::aid-ps949>3.0.co;2-f

文献信息

• A general photocatalytic hydrodefluorination and defluoroalkylation of electronically-variable ArCF₃ by changing commercially-available arenethiolates
  作者：Yuanyang Jiang、Chenxiu Han、Zipeng Guo、Zhenyang Dai、Guangchao Liang、Shuo Guo、Nathaniel K. Szymczak、Pingping Tang

  DOI：10.1039/d3gc05041f

  日期：——

  Although defluorinative functionalization of trifluoromethylarenes has been studied by several research groups, different kinds of catalysts are required accordingly based on specific substrate families to obtain the corresponding RCF2Ar compounds. Herein, we report a general photocatalytic approach for the selective hydrodefluorination (HDF) and defluoroalkylation (DFA) of ArCF3. Using electronically-different

  尽管多个研究小组对三氟甲基芳烃的脱氟官能化进行了研究，但根据特定的底物族，需要相应不同种类的催化剂才能获得相应的RCF 2 Ar化合物。在此，我们报告了一种用于ArCF 3选择性加氢脱氟（HDF）和脱氟烷基化（DFA）的通用光催化方法。使用电子不同的芳烃硫醇盐作为光敏剂，从多种电子可变的三氟甲基芳烃（包括天然产物和生物活性分子）合成了 88 种 α,α-二氟甲基化合物。我们的机理研究揭示了光诱导的电子供体-受体 (EDA) 络合，然后是硅烷辅助的 C-F 键激活。
• COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY
  申请人：Annapurna Bio Inc.

  公开号：EP3860998A1

  公开（公告）日：2021-08-11
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ DU RÉCEPTEUR DE L'APJ
  申请人：ANNAPURNA BIO INC

  公开号：WO2020073011A1

  公开（公告）日：2020-04-09

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.